Hologic, Inc. has received $0.51 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 12 Financial Advisor in the Stock Trading Firms. Among 12 Analysts, Bottom line EPS Estimate for the current quarter is $0.47 while the top line estimate is $0.52 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 9.78%.
Hologic, Inc. reported better than expected with a surprise EPS of 4% or $0.02 during its most recent quarterly earnings. The Actual EPS was $0.52 compared to the Estimated EPS of $0.5. Marlborough based Hologic, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Feb 01, 2017.
Hologic, Inc. has a Price to Earnings ratio of 20.48 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 5.2. For the Most Recent Fiscal Year, Hologic, Inc. has a price to cash ratio of 10.84. For the Trailing twelve month period, company showed a Net Profit Margin of 11.68% and Return on Equity of the stock is 26.76%.
In the last quarter, Hologic, Inc. reported Annual Earnings of $0.52. Based on the filings, last years Annual Earnings was, $1.96. In the last Quarter, HOLX reported a surprise Earnings per Share of 4% . The consensus estimate for current quarter is $0.51 and for the current fiscal year, the estimate is $2.14. For the Next fiscal year, the estimate is $2.34 based on the consensus.
Hologic, Inc. (NASDAQ:HOLX) : On Tuesday heightened volatility was witnessed in Hologic, Inc. (NASDAQ:HOLX) which led to swings in the share price. The stock opened for trading at $40.16 and hit $40.54 on the upside , eventually ending the session at $40.53, with a gain of 0.97% or 0.39 points. The heightened volatility saw the trading volume jump to 2,497,433 shares. The 52-week high of the share price is $41.01 and the company has a market cap of $11,318 million. The 52-week low of the share price is at $31.84 .
Hologic Inc. is a leading supplier of high quality, innovative and clinically valuable diagnostic systems and tests. The company develops, manufactures and markets X-ray bone densitometers and ultrasound bone analyzers that address a growing market for osteoporosis prevention and treatment — a key element of womens health care. The systems are used by more leading medical schools, universities and osteoporosis opinion leaders than any other bone densitometer.